Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care (Q38979257)

8 September 2017

1 reference

title

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care (English)

1 reference

8 September 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ann H Partridge

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Olivia Pagani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Aron Goldhirsch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Judy E Garber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

12 October 2016

1 reference

Breast Cancer Research and Treatment

8 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

160

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

393-410

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27734215%20AND%20SRC:MED&resulttype=core&format=json

Inherited susceptibility to common cancers

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The emerging landscape of breast cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Risk of breast cancer in male BRCA2 carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Clear Cell Carcinoma of the Breast: A Rare Breast Cancer Subtype - Case Report and Literature Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Exemestane for breast-cancer prevention in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Lifetime cancer risks in individuals with germline PTEN mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Risks of less common cancers in proven mutation carriers with lynch syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Risk of pancreatic cancer in families with Lynch syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Breast-cancer risk in families with mutations in PALB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Rare variants in the ATM gene and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Mutations in BRIP1 confer high risk of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

PARP Inhibitors for the Treatment and Prevention of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Routine TP53 testing for breast cancer under age 30: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Early onset HER2‐positive breast cancer is associated with germline TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Laparoscopic prophylactic total gastrectomy with linear stapler side-to-side esophagojejunal anastomosis for hereditary diffuse gastric cancer syndrome in 2 siblings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Bilateral large-cell calcifying Sertoli cell tumor of the testes with Peutz-Jeghers syndrome: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The frequency of Muir-Torre syndrome among Lynch syndrome families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Breast cancer risk and clinical implications for germline PTEN mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Clinical characteristics of Peutz-Jeghers syndrome in Korean polyposis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Genotype-phenotype correlations in Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Disseminated cervical adenoma malignum and bilateral ovarian sex cord tumors with annular tubules associated with Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Peutz-Jeghers syndrome: a systematic review and recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Gene-panel sequencing and the prediction of breast-cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

PALB2 regulates recombinational repair through chromatin association and oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

PALB2/FANCN: Recombining Cancer and Fanconi Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Targeting chk2 kinase: molecular interaction maps and therapeutic rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

CHEK2 is a multiorgan cancer susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

ATM mutations in patients with hereditary pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Variants in the ATM gene associated with a reduced risk of contralateral breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Molecular genetics of neurofibromatosis type 1 (NF1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Incidence and mortality of neurofibromatosis: a total population study in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Genetic testing for RAD51C mutations: in the clinic and community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Heterozygous mutations in DNA repair genes and hereditary breast cancer: a question of power

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

The role of the genetic counsellor: a systematic review of research evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Genetic counsellors in Sweden: their role and added value in the clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9

Genetic professionals' views on genetic counsellors: a French survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4003-9